All In Biotech

Drug Trial Radar · NCT00086255

Tiagabine for the Treatment of Cocaine Dependence - 1

Tiagabine for the Treatment of Cocaine Dependence

Last checked: Nov 19, 2026Latest source record: Jan 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

140

Actual

Start

Oct 2002

Primary completion

Not stated

Study completion Jun 2004

Sponsor

Sponsor type
NIH
Collaborators
University of Cincinnati
First posted
Jun 30, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess tiagabine for the treatment of cocaine dependence.

Conditions

  • Cocaine-Related Disorders

Interventions

  • TiagabineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Drug use
  2. Cocaine use
  3. Addiction severity
  4. Clinical improvement

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Boston University Medical Center

    Boston, Massachusetts

  • Cincinnati VA Medical Center

    Cincinnati, Ohio

  • Dayton VA Medical Center

    Dayton, Ohio

  • University of Texas Hlth Sci Ctr Houston

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.